Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]
Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy.[4]
^Wyeth Product Pipeline Archived 2007-05-09 at the Wayback Machine, Wyeth, Website accessed April 22, 2007
^"Study Evaluating MYO-029 in Adult Muscular Dystrophy". clinicaltrials.gov. 24 June 2007. Retrieved 2023-02-19.
^"Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029". www.medicalnewstoday.com (Press release). 28 February 2005. Archived from the original on 15 March 2005. Retrieved 2023-02-19.{{cite press release}}: CS1 maint: unfit URL (link)
^"Blocking Myostatin Proves Beneficial in Mice with DMD". MDA Research News. 27 November 2002. Archived from the original on 22 December 2002. Retrieved 2023-02-19.
Stamulumab (MYO-029) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab...
disable myostatin, including apitegromab, domagrozumab, landogrozumab, and stamulumab. Another form of myostatin inhibition is gene therapy. Another monoclonal...
the market. An antibody genetically engineered to neutralize myostatin, stamulumab, which was under development by pharmaceutical company Wyeth, is no longer...
that calcium dysregulation played a part in muscle cell death. MYO-029 (Stamulumab), an antibody that inhibits myostatin, was developed to promote muscle...
Germany: John Wiley & Sons. p. 2131. ISBN 978-3-527-32937-3. Entry on Stamulumab. at: Römpp Online. Georg Thieme Verlag, retrieved 2021-11-17. AGN (1931)...
Global Information
(what is this?) (verify)